Status: Recruiting
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
The purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD with chronic bronchitis.
Participants needed: 402
Trial details
Phase: Phase 2Age: 40-80Biological sex: AllType: InterventionalSponsor: UCB Biopharma SRLUpdated: Aug 17, 2026Locations: 3
Eligibility criteria
Participant must be aged ≥40 to ≤80 years of age, inclusive, at the time of sign... [+9]
Participant has any history or presence of any medical or psychiatric condition,... [+11]